Stage III Grade 3 Follicular Lymphoma Completed Phase 2 Trials for Bendamustine (DB06769)

IndicationStatusPhase
DBCOND0028630 (Stage III Grade 3 Follicular Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01286272Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin LymphomaTreatment